The short version of GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
== Activation == Chymotrypsinogen must be inactive until it gets to the digestive tract, in order to prevent damage to the pancreas or any other organs. It is activated by another enzyme called trypsin. The active form is called π-chymotrypsin and is used to create α-chymotrypsin. Trypsin cleaves the peptide bond in chymotrypsinogen between arginine-15 and isoleucine-16. This creates two peptides within the π-chymotrypsin molecule, held together by a disulfide bond. One π-chymotrypsin acts on another by breaking a leucine and serine peptide bond. The activated π-chymotrypsin reacts with other π-chymotrypsin molecules to cleave and remove two dipeptides: serine-14–arginine-15 and threonine-147–asparagine-148. This reaction produces α-chymotrypsin. The yield of α-chymotrypsin can be affected by inhibitors such as hydrocinnate and also by pH, temperature and calcium chloride. The activation process can be studied using fluorescence probe 2-p-toluidinylnaphthalene-6-sulfonate (TNS). TNS forms covalent bonds with chymotrypsinogen and as the bonds break to form chymotrypsin in the presence of trypsin, the fluorescence increases.
According to a 2003 report by Human Rights Watch, an estimated 15 million children in debt bondage in India work in slavery-like conditions to pay off their family's debts. Slavoj Žižek asserts that new forms of contemporary slavery have been created in the post-Cold War era of global capitalism, including migrant workers deprived of basic civil rights on the Arabian Peninsula, the total control of workers in Asian sweatshops and the use of forced labor in the exploitation of natural resources in Central Africa.
S2CID 17336375. Wickramasinghe, N. C. (2010). "The astrobiological case for our cosmic ancestry". International Journal of Astrobiology. 9 (2): 119–129. Bibcode:2010IJAsB...9..119W. doi:10.1017/S1473550409990413. S2CID 13978227. Wickramasinghe, N.C.; Wallis, J.; Wallis, D.H.; Schild, R.E.; Gibson, C.H. (2012). "Life-bearing planets in the solar vicinity". Astrophysics and Space Science. 341 (2): 295–9. Bibcode:2012Ap&SS.341..295W. doi:10.1007/s10509-012-1092-8. S2CID 120484953. Chandra Wickramasinghe, A Journey with Fred Hoyle: The Search for Cosmic Life, World Scientific Publishing, 2005, ISBN 981-238-912-1 Janaki Wickramasinghe, Chandra Wickramasinghe and William Napier, Comets and the Origin of Life, World Scientific Publishing, 2009, ISBN 981-256-635-X Chandra Wickramasinghe and Daisaku Ikeda, Space and Eternal Life, Journeyman Press, 1998, ISBN 1-85172-060-X
Sources: en.wikipedia.org
US officials said on 30 October 2025 they had identified "targets that sit at the nexus of the drug gangs and the Maduro regime", including facilities such as ports and airstrips, including military facilities, allegedly uses for drug trafficking. On 22 December, referring to the military buildup and ongoing airstrikes, Trump stated: "Soon we will be starting the same program on land." Trump announced on 29 December the first strike on a land target in Venezuela, stating that a marine facility used for loading drug boats had been hit. Trump had previously mentioned on 26 December a strike he said happened two nights earlier, likely on 24 December. Trump gave no details about the location of the facility or what entity, military or otherwise, was responsible for the strike. As of 30 December, there were no official statements from either the US or Venezuela confirming the details of any strike. CNN reported that unnamed sources said Trump was referencing a drone strike with no casualties, conducted by the CIA, with intelligence support from US military forces, on a "remote dock on the Venezuelan coast that the US government believed was being used by the Venezuelan gang Tren de Aragua to store drugs and move them onto boats for onward shipping". Other incidents in December were speculated to be land targets mentioned by Trump. Colombia's president Petro stated that the target was a factory near Maracaibo that he suspected was used by ELN to fabricate cocaine from coca paste.
A molecular assembler, as defined by K. Eric Drexler, is a "proposed device able to guide chemical reactions by positioning reactive molecules with atomic precision". A molecular assembler is a molecular machine. Some biological molecules such as ribosomes fit this definition as biological machines. This is because they receive instructions from messenger RNA and then assemble specific sequences of amino acids to construct protein molecules.
=== 2011–2017: The Only Way Is Essex, I'm a Celebrity...Get Me Out of Here! and Celebrity Big Brother === In January 2011, Julie Childs, mother of Collins' friend Amy, suggested to producers of the ITV2 reality series The Only Way Is Essex that Collins would be an appropriate subject. They visited Collins' house and subsequently filmed her and her friends for two weeks. After returning to work as a car sales executive for a week, she was cast in the programme and began appearing in The Only Way Is Essex from its second series beginning in March 2011. Her first scene saw her attempting to sell a car to Kirk Norcross and taking him for a test drive. Collins ultimately quit her job to appear on the programme full time, and was paid £50 a day for her early appearances on the show, which she described as a "massive risk". Her mother Joan joined the programme during the fifth series in April 2012. From September 2011 until March 2013, Collins wrote a regular column in the tabloid magazine Closer. In April 2013, she released her debut autobiography Basically...: My Life as a Real Essex Girl, which became a bestseller in its first week of release. In January 2014, Collins took part in the second series of the ITV diving competition Splash!. During training, Collins suffered severe bruising and admitted she had to overcome a fear of water. She became the third celebrity to be eliminated after losing the splash-off to Michaela Strachan in the first heat. In November 2014, she took part in the fourteenth series of I'm a Celebrity...Get Me Out of Here! on ITV.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.